Our approach to venture investments
We strive to invest in companies that develop innovative drugs, medical devices and diagnostics.
We focus on generating strong financial returns from our portfolio of venture companies. We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective.
With colleagues on the ground in Copenhagen, London, Singapore, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge.
We primarily invest in biotechnology and medical technology. Within biotech we primarily invest in companies with clinical stage compounds. In medtech, we invest in commercial stage companies.
We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences.
During 2021, Novo Ventures executed 46 investments. We deployed DKK 3.2 billion during the year. Investment highlights include:
• Verve Therapeutics, a gene editing company hoping to lower LDL cholesterol for familial hypercholesterolemia and one of the first in vivo gene editing therapies to begin clinical trials
• Hummingbird Biosciences, a company using a systems biology approach to antibody discovery and development, and our first venture portfolio company with headquarters in Asia
• Numab Therapeutics, a next generation antibody fragment platform company whose lead programme has the potential to become new standard of care in immune checkpoint therapy
• Noom, a leading, high growth, global digital health platform